[Preventive long-term intravenous immunoglobulin infusion in children with acute lymphatic leukemia. II. Zymosan opsonization is decreased and is not increased by IgG infusions].
Zymosan opsonisation was determined in sera of 38 normal individuals and 20 children with acute lymphocytic leukemia (ALL). All patients underwent chemotherapy according to the CoALL 82 protocol. Intravenous gammaglobulin (ivGG) was given prophylactically to replace deficient specific antibodies. Zymosan opsonisation in normal sera ranged from 65% to 133% of a serum pool, whereas sera of children with ALL exhibited markedly decreased opsonisation ranging from 7% to 141% (of the pooled serum standard) at different times during an observation period of 20 months. No significant changes could be observed over time, neither induced by the ivGG infusion itself (short term effect) nor during the 20 months observation period (long term effect). Before ivGG therapy was initiated, a positive correlation was found between zymosan opsonisation and complement parameters (CH 50: p less than 0.01; AP 50; p less than 0.001; C3: p less than 0.05). No correlation could be noted between zymosan opsonisation and IgG concentration. Experiments with complement deficient sera clearly demonstrated the dependence of zymosan opsonisation from complement function. In contrast, sera with little or no IgG but intact complement, showed normal zymosan opsonisation. Deficient zymosan opsonisation might contribute to the immune deficiency of ALL patients. The present study suggests, that the zymosan opsonisation cannot be corrected by ivGG infusions.
Nürnberger
W
W
Abteilung für Allgemeine Pädiatrie und Neonatologie an der Kinderklinik, Universität Düsseldorf.
Willers
R
R
Schroten
H
H
Bünning
G
G
Göbel
U
U
Wahn
V
V
D000361:Agammaglobulinemia / Q000276:immunology; D002634:Chemotaxis, Leukocyte; D002648:Child; D003165:Complement System Proteins / Q000172:deficiency; D006098:Granulocytes / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D007945:Leukemia, Lymphoid / Q000276:immunology*; D008163:Luminescent Measurements; D009895:Opsonin Proteins / Q000502:physiology*; D010587:Phagocytosis; D015054:Zymosan / Q000276:immunology*
D007074:Immunoglobulin G; D009895:Opsonin Proteins; D003165:Complement System Proteins; D015054:Zymosan
Prophylaktische Langzeit-i.v.-Immunglobulin-Infusion bei Kindern mit akuter lymphatischer Leukämie. II. Die Zymosan-Opsonisierung ist erniedrigt und wird durch IgG-Infusionen nicht gesteigert.